Corporate Profile
Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
May 13, 2022
May 11, 2022
May 04, 2022
Events
Jun 9, 2022 at 10:00 AM EDT
May 25, 2022 at 3:30 PM EDT
May 1 - May 4, 2022
Latest SEC Filings
Form | Filing date | Description |
---|---|---|
10-K | Annual report which provides a comprehensive overview of the company for the past year |
|
10-Q | Quarterly report which provides a continuing view of a company's financial position |
|
10-Q | Quarterly report which provides a continuing view of a company's financial position |